The Kappa Free Light Chains Index in Multiple Sclerosis: From Emerging Evidence to Clinical Application
Journal of Neurochemistry · 2026-04 · 170 (4)
DOI: 10.1111/jnc.70423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 01.04.2026. Verfasst von Noé Verchere und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Laboratory, CHU Pontchaillou, Rennes, France. Hauptthemen laut MEDLINE: Multiple Sclerosis, Immunoglobulin kappa-Chains. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The kappa free light chain (KFLC) index is a promising biomarker for detecting intrathecal immunoglobulin synthesis in multiple sclerosis (MS), offering a quantitative and automated alternative to oligoclonal bands (OCBs). However, its use in clinical practice is limited by heterogeneous thresholds and a lack of standardized diagnostic algorithms. Objective to develop and validate a biological diagnostic algorithm for MS that fully integrates the KFLC‐index alongside current recommended CSF biomarkers, particularly CSF‐restricted OCBs. We conducted a prospective, monocentric study including 198 patients undergoing lumbar puncture for suspected neurological disease. Patients were classified as having MS (including CIS/RIS) or non‐inflammatory neurological disorders. Paired cerebrospinal fluid and serum KFLC and LFLC were quantified using a turbidimetric assay (Optilite, The Binding Site). Diagnostic performance was assessed by ROC analysis. A diagnostic algorithm was developed and validated in an independent cohort. In the derivation cohort ( n = 80), the KFLC‐index showed excellent accuracy (AUC = 0.93). An optimal threshold of 20.27 provided 80.6% sensitivity and 100% specificity. A lower threshold of 3 increased sensitivity (96.8%) but reduced specificity (26.5%). Application of the diagnostic algorithm to the replication cohort ( n = 70) confirmed the absence of false positive and false negative results for threshold values. Systematic OCBs testing enhanced interpretation in intermediate KFLC‐index ranges (3–20). The algorithm's performance was consistent with previously published thresholds. The KFLC‐index is a robust biomarker for MS diagnosis. Integration into a tiered algorithm offers excellent diagnostic performance, though local validation remains essential before broad clinical adoption. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry Laboratory, CHU Pontchaillou, Rennes, France.
- Neurology, CHU Pontchaillou, Rennes, France.
- Biostatistics, CHU Pontchaillou, Rennes, France.
- Univ Rennes, CHU Rennes, INSERM, NUMECAN, Rennes, France.
- Immunology Laboratory, CHU Pontchaillou, Rennes, France.
- Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) UMR_S 1085, Rennes, France.
Zitieren
APA
Verchere, N., Roult, S., Michel, L., Le Page, E., Rousseau, C., Messaoudi, K., Hasbini, R., Bendavid, C., Dumontet, E., & Moreau, C. (2026). The Kappa Free Light Chains Index in Multiple Sclerosis: From Emerging Evidence to Clinical Application. Journal of Neurochemistry, 170(4). https://doi.org/10.1111/jnc.70423
Vancouver
Verchere N, Roult S, Michel L, Le Page E, Rousseau C, Messaoudi K, et al. The Kappa Free Light Chains Index in Multiple Sclerosis: From Emerging Evidence to Clinical Application. Journal of Neurochemistry. 2026;170(4). doi:10.1111/jnc.70423
BibTeX
@article{Verchere2026,
author = {Verchere, Noé and Roult, Ségolène and Michel, Laure and Le Page, Emmanuelle and Rousseau, Chloé and Messaoudi, Khaled and Hasbini, Riwan and Bendavid, Claude and Dumontet, Erwan and Moreau, Caroline},
title = {The Kappa Free Light Chains Index in Multiple Sclerosis: From Emerging Evidence to Clinical Application},
journal = {Journal of Neurochemistry},
year = {2026},
volume = {170},
number = {4},
doi = {10.1111/jnc.70423}
}
EUVIMED